143547-74-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Benzhydryl-1H-pyrazole, 97 is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs, contributing to the advancement of medicine and healthcare.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Benzhydryl-1H-pyrazole, 97 is utilized as a component in the creation of agrochemicals. Its properties make it suitable for use in the development of pesticides, herbicides, and other agricultural chemicals, helping to improve crop yields and protect plants from pests and diseases.
Used in Research and Development:
5-Benzhydryl-1H-pyrazole, 97 is used in research and development for its potential applications in drug discovery and other fields of chemistry. Its unique properties and reactivity make it a valuable tool for scientists and researchers working on the development of new chemical compounds and materials.
Safety and Storage:
5-Benzhydryl-1H-pyrazole, 97 should be handled with care and stored in a cool, dry place away from sources of ignition and incompatible materials. Proper safety measures should be taken during its use to ensure the safety of individuals and the environment.

Upstream product

• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 781-35-1 1,1-diphenylacetone 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 143547-54-0 methyl 9-<3-(diphenylmethyl)-1H-pyrazol-1-yl>nonanoate 
• 143547-56-2 methyl 9-<5-(diphenylmethyl)-1H-pyrazol-1-yl>nonanoate 
• 143547-55-1 9-(5-Benzhydryl-pyrazol-1-yl)-nonanoic acid 
• 143547-53-9 9-(3-Benzhydryl-pyrazol-1-yl)-nonanoic acid 

Relevant academic research and scientific papers

The coordination chemistry of the hydrotris(3-diphenylmethyl-pyrazol-1-yl)borate (TpCHPh2) ligand

The new ligand, hydrotris[3-(diphenylmethyl)pyrazol-1-yl]borate, Tp CHPh2, has been synthesized and its coordination chemistry was compared with that of the analogous Tpipr. The new ligand was converted to a variety of complexes, such as M[TpCHPh2]X (M = Co, Ni, Zn: X = Cl, NCO, NCS), Pd[TpCHPh2][η3-methallyl], Co[TpCHPh2](acac), and Co[TpCHPh2](scorpionate ligand). Compounds Tl[TpCHPh2], 1, Co[TpCHPh2]Cl, 2, Co[Tp CHPh2](NCS)(DMF), 3, Ni[TpCHPh2](NCS)(DMF)2, 4, Co[TpCHPh2](acac), 5, Co[TpCHPh2][Ph2Bp], 6, Co[TpCHPh2][Bpph], 7, Co[TpCHPh2][Tp], 8, and (Ni[TpCHPh2])2[C2O4](H 2O)2, 9, were structurally characterized.

Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety

Structural modification of [2-(2-benzhydryloxyiminopentyl)-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid (4), previously identified as a PGI2 agonist without a PG skeleton, was examined. Conversion of the oxime moiety in 4 to the pyrazole led to [2-(4-benzhydrylpylazoyl)methyl-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid (34) which strongly inhibited ADP-induced aggregation of human platelets in vitro.

Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety

4,5-Diphenyl-2-oxazolenonanoic acid (2) and 2-[3-[2-(4,5-diphenyl-2- oxazolyl)ethyl]phenoxy]acetic acid (3) were previously identified as nonprostanoid prostacyclin (PGI2) mimetics that inhibit ADP-induced aggregation of human platelets in vitro. The effects on biological activity of substitution and structural modification of the 4- and 5-phenyl rings of 3 was examined. Potency showed a marked sensitivity to the introduction of substituents to these aromatic rings and only the bis-4-methyl derivative 9j, IC50 = 0.34 μM, demonstrated enhanced potency compared to the parent structure 3, IC50 = 1.2 μM. Substitution at the ortho or meta positions of the phenyl rings, replacement by thiopheneyl or cyclohexyl moieties, or constraining in a planar phenanthrene system resulted in compounds that were less effective inhibitors of ADP-induced platelet aggregation. In contrast, variation of the heterocycle moiety revealed a much less stringent SAR and many 5- and 6-membered heterocycles were found to effectively substitute for the oxazole ring of 2 and 3. The diphenylmethyl moiety functioned as an effective isostere for 4,5-diphenylated heterocycles since 13aad showed similar platelet inhibitory activity to 3. With the exception of the 3,4,5- triphenylpyrazole derivative 13g, compounds presenting the (m- ethylphenoxy)acetic acid side chain discovered with 3 demonstrated enhanced potency compared to the analogously substituted alkanoic acid derivative. The structure-activity findings led to a refinement of a model of the nonprostanoid PGI2 mimetic pharmacophore.